- Home
- OBIO vs CBUS Comparison
OBIO vs CBUS Comparison
Compare OBIO & CBUS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | OBIO | CBUS |
|---|---|---|
| Founded | 2017 | 2010 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medicinal Chemicals and Botanical Products | Agricultural Chemicals |
| Sector | Health Care | Industrials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 237.2M | 197.5M |
| IPO Year | 2020 | 2017 |
Fundamental Metrics
Financial Performance| Metric | OBIO | CBUS |
|---|---|---|
| Price | $4.37 | $3.68 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 5 | 2 |
| Target Price | $14.25 | ★ $20.00 |
| AVG Volume (30 Days) | 206.0K | ★ 566.4K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 58.27 |
| EPS | ★ N/A | N/A |
| Revenue | $2,638,000.00 | ★ $4,262,000.00 |
| Revenue This Year | $36.66 | N/A |
| Revenue Next Year | $2.30 | $99.13 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ 134.56 |
| 52 Week Low | $2.20 | $1.09 |
| 52 Week High | $5.42 | $3.80 |
Technical Indicators
Market Signals| Indicator | OBIO | CBUS |
|---|---|---|
| Relative Strength Index (RSI) | 59.30 | 72.16 |
| Support Level | $4.00 | $1.34 |
| Resistance Level | $5.00 | N/A |
| Average True Range (ATR) | 0.26 | 0.34 |
| MACD | 0.07 | 0.11 |
| Stochastic Oscillator | 90.00 | 93.19 |
Price Performance
Historical ComparisonAbout OBIO Orchestra BioMed Holdings Inc.
Orchestra BioMed Holdings Inc is a biomedical innovation company accelerating high-impact technologies to patients through risk-reward sharing partnerships. Its partnership-enabled business model focuses on forging strategic collaborations with medical device companies to drive the commercialization of the products it develops. The company's flagship product candidates include BackBeat Cardiac Neuromodulation Therapy (CNT) for the treatment of hypertension and Virtue Sirolimus AngioInfusionBalloon (SAB) for the treatment of atherosclerotic artery disease.
About CBUS Cibus Inc.
Cibus Inc is a biotechnology company. The company develops and commercializes a proprietary gene-editing technology, Rapid Trait Development System that integrates crop specific cell biology platforms with a series of gene editing technologies. The company's primary business is the development of plant traits that help address specific productivity or yield challenges in farming such as traits addressing plant agronomy, disease, insects, weeds, nutrient-use, or the climate.